Long-term follow-up of metil aminolevulinate (MAL)-PDT in difficult-to-treat cutaneous Bowen's disease

Stefano Cavicchini, Stefano Maria Serini, Roberta Fiorani, Valentina Girgenti, Massimo Ghislanzoni, Francesco Sala

Research output: Contribution to journalArticle

Abstract

Bowen's disease (BD) is a form of intraepidermal squamous cell carcinoma, which is clinically characterized by gradually enlarging, well-demarcated erythematous plaques with irregular borders and surface crusting or scaling, affecting primarily the elderly. BD often presents with lesions difficult to treat with standard therapy as surgery, cryosurgery, or 5-fluorouracil (5-FU) for the risk of significantly poor cosmetic outcome, failure rate, and adverse events, related mainly to the age of the patients. Topical PDT with methyl aminolevulinate (MAL) represents a valid and approved therapy for BD lesions in many cases, especially for lesions located at poor healing sites or for large patches of disease, due to its high efficacy coupled with good tolerability and tissue-sparing attitude. In this study, we sought to investigate the efficacy, safety, and cosmetic outcome of MAL-PDT in a series of patients with BD lesions which were challenging to treat for clinical, surgical, and patient-related reasons, such as size of the lesion, difficult surgical approach for anatomical sites, or age of patients and request of the best cosmetic result. We also performed a long-term follow-up to assess recurrence rates and eventual late-onset adverse events.

Original languageEnglish
Pages (from-to)1002-1005
Number of pages4
JournalInternational Journal of Dermatology
Volume50
Issue number8
DOIs
Publication statusPublished - Aug 2011

Fingerprint

Bowen's Disease
Skin Diseases
Cosmetics
Cryosurgery
Fluorouracil
Squamous Cell Carcinoma
Safety
Recurrence
1-phenyl-3,3-dimethyltriazene
Therapeutics

ASJC Scopus subject areas

  • Dermatology

Cite this

Long-term follow-up of metil aminolevulinate (MAL)-PDT in difficult-to-treat cutaneous Bowen's disease. / Cavicchini, Stefano; Serini, Stefano Maria; Fiorani, Roberta; Girgenti, Valentina; Ghislanzoni, Massimo; Sala, Francesco.

In: International Journal of Dermatology, Vol. 50, No. 8, 08.2011, p. 1002-1005.

Research output: Contribution to journalArticle

Cavicchini, Stefano ; Serini, Stefano Maria ; Fiorani, Roberta ; Girgenti, Valentina ; Ghislanzoni, Massimo ; Sala, Francesco. / Long-term follow-up of metil aminolevulinate (MAL)-PDT in difficult-to-treat cutaneous Bowen's disease. In: International Journal of Dermatology. 2011 ; Vol. 50, No. 8. pp. 1002-1005.
@article{0aab154c785e4a61a9fc001cf8c6fe83,
title = "Long-term follow-up of metil aminolevulinate (MAL)-PDT in difficult-to-treat cutaneous Bowen's disease",
abstract = "Bowen's disease (BD) is a form of intraepidermal squamous cell carcinoma, which is clinically characterized by gradually enlarging, well-demarcated erythematous plaques with irregular borders and surface crusting or scaling, affecting primarily the elderly. BD often presents with lesions difficult to treat with standard therapy as surgery, cryosurgery, or 5-fluorouracil (5-FU) for the risk of significantly poor cosmetic outcome, failure rate, and adverse events, related mainly to the age of the patients. Topical PDT with methyl aminolevulinate (MAL) represents a valid and approved therapy for BD lesions in many cases, especially for lesions located at poor healing sites or for large patches of disease, due to its high efficacy coupled with good tolerability and tissue-sparing attitude. In this study, we sought to investigate the efficacy, safety, and cosmetic outcome of MAL-PDT in a series of patients with BD lesions which were challenging to treat for clinical, surgical, and patient-related reasons, such as size of the lesion, difficult surgical approach for anatomical sites, or age of patients and request of the best cosmetic result. We also performed a long-term follow-up to assess recurrence rates and eventual late-onset adverse events.",
author = "Stefano Cavicchini and Serini, {Stefano Maria} and Roberta Fiorani and Valentina Girgenti and Massimo Ghislanzoni and Francesco Sala",
year = "2011",
month = "8",
doi = "10.1111/j.1365-4632.2011.04962.x",
language = "English",
volume = "50",
pages = "1002--1005",
journal = "International Journal of Dermatology",
issn = "0011-9059",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Long-term follow-up of metil aminolevulinate (MAL)-PDT in difficult-to-treat cutaneous Bowen's disease

AU - Cavicchini, Stefano

AU - Serini, Stefano Maria

AU - Fiorani, Roberta

AU - Girgenti, Valentina

AU - Ghislanzoni, Massimo

AU - Sala, Francesco

PY - 2011/8

Y1 - 2011/8

N2 - Bowen's disease (BD) is a form of intraepidermal squamous cell carcinoma, which is clinically characterized by gradually enlarging, well-demarcated erythematous plaques with irregular borders and surface crusting or scaling, affecting primarily the elderly. BD often presents with lesions difficult to treat with standard therapy as surgery, cryosurgery, or 5-fluorouracil (5-FU) for the risk of significantly poor cosmetic outcome, failure rate, and adverse events, related mainly to the age of the patients. Topical PDT with methyl aminolevulinate (MAL) represents a valid and approved therapy for BD lesions in many cases, especially for lesions located at poor healing sites or for large patches of disease, due to its high efficacy coupled with good tolerability and tissue-sparing attitude. In this study, we sought to investigate the efficacy, safety, and cosmetic outcome of MAL-PDT in a series of patients with BD lesions which were challenging to treat for clinical, surgical, and patient-related reasons, such as size of the lesion, difficult surgical approach for anatomical sites, or age of patients and request of the best cosmetic result. We also performed a long-term follow-up to assess recurrence rates and eventual late-onset adverse events.

AB - Bowen's disease (BD) is a form of intraepidermal squamous cell carcinoma, which is clinically characterized by gradually enlarging, well-demarcated erythematous plaques with irregular borders and surface crusting or scaling, affecting primarily the elderly. BD often presents with lesions difficult to treat with standard therapy as surgery, cryosurgery, or 5-fluorouracil (5-FU) for the risk of significantly poor cosmetic outcome, failure rate, and adverse events, related mainly to the age of the patients. Topical PDT with methyl aminolevulinate (MAL) represents a valid and approved therapy for BD lesions in many cases, especially for lesions located at poor healing sites or for large patches of disease, due to its high efficacy coupled with good tolerability and tissue-sparing attitude. In this study, we sought to investigate the efficacy, safety, and cosmetic outcome of MAL-PDT in a series of patients with BD lesions which were challenging to treat for clinical, surgical, and patient-related reasons, such as size of the lesion, difficult surgical approach for anatomical sites, or age of patients and request of the best cosmetic result. We also performed a long-term follow-up to assess recurrence rates and eventual late-onset adverse events.

UR - http://www.scopus.com/inward/record.url?scp=79960639602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960639602&partnerID=8YFLogxK

U2 - 10.1111/j.1365-4632.2011.04962.x

DO - 10.1111/j.1365-4632.2011.04962.x

M3 - Article

C2 - 21781078

AN - SCOPUS:79960639602

VL - 50

SP - 1002

EP - 1005

JO - International Journal of Dermatology

JF - International Journal of Dermatology

SN - 0011-9059

IS - 8

ER -